bioSeedin InnoXpo CGT roadshow is about to start online! All the six presenting companies and attending judges have been confirmed. This CGT roadshow will cover CAR-T, CAR-NK and ACP therapies for cancer, heart disease, infectious disease and neurological disease and immune disease. This time, we rise the Q&A time to 5 minutes to give more chances for deeper communication among speakers, judges and audiences.

 

Event information

Topic: The future of Cell and Gene Therapy

Time: Thursday, April 18th, 2024 12pm EST

In other time zone:

Apr 18th, 2024 9am PST

Apr 18th, 2024 6pm CET

Apr 19th, 2024 12am BJT

 

 

Judges:

• Mark Wong

Business Development Director - Probatech

• Natalia Novac

Investor, Partner – Delin Ventures

• Lan Cao

VP Lead of Cell Tx - Takeda

 

 

Agenda (EST):

• 12:00 pm - 12:10 pm

Roadshow opening & Judge introduction

 

• 12:10 pm - 12:25 pm

Teneura Therapeutics

Speaker: Niels von Wardenburg, Founder

Keywords: Neurological Autoimmune Diseases, NMDAR Encephalitis, Myasthenia Gravis, Autologous T Cell Therapies, Chimeric Autoantibody Receptor (CAAR), Chimeric Antigen Receptor (CAR)

 

• 12:25 pm - 12:40 pm

Mabswitch

Speaker: Yemi Onakunle, PhD, MBA (Founder & CEO)

Keywords: CAR-T, T cell therapy, UNASMA, Auto-immune diseases, Infectious diseases

 

• 12:40 pm - 12:55 pm

Immunofoco 

Speaker: Wayne He (BD Director)

Keywords: Peri Cruiser Platform, T-booster platform, Solid tumors, T-cell, CAR-T

 

• 12:55 pm - 01:10 pm

Celyad Oncology

Speaker:

Keywords: shRNA, Immunotherpay, Gene modulation, CAR-T, Multiplexing, Solid tumors

 

• 01:10 pm - 01:25 pm

Allife Medicine

Speaker: Shengjiang Tan (Co-founder)

Keywords: iPSC technology, CAR-NK Immunotherapy, Endothelial Progenitor Cells (EPC), cute ischemic stroke 

 

• 01:25 pm - 01:40 pm

Hemostemix 

Speaker: Thomas Smeenk (CEO)

Keywords: Angiogenic Cell Precursors ("ACP"), autologous (patient's own) treatment, chronic limb threatening ischemia (“CLTI”)

 

• 01:40 pm - 01:50 pm

Roadshow closing & Next Roadshow Announcement

 

 

Judge introduction

• Mark Wong 

Business Development Director - Probatech

Mark has been supporting business development in the biomedical science industry for over 20 years with wide-ranging domain expertise in drug discovery, regulatory development and translational science. He has extensive operational and corporate experience in both high growth start-ups and multinationals. In recent years he has been supporting business development and strategy for VRise Therapeutics and helping Probatech connect early-stage innovation to the pharma ecosystem.

 

• Natalia Novac 

Investor – Delin Ventures  

Professional investor and drug hunter with several years investment, company building expertise and more than 15 years experience in pharmaceutical industry with solid academic background in oncology, endocrinology and immunology. Board member of AI Drug Discovery & therapeutic development companies. Broad network and deep pharma experience through roles in drug discovery, development, commercial and strategic management to business development and corporate investment. 

 

• Lan Cao 

Takeda - VP Lead of Cell Tx  

With about 18 years of industry experience and six years of experience at Takeda, Lan holds a pivotal role as the Vice President and Head of Cell Therapy Innovation. He has demonstrated expertise in leading cross-functional teams across various aspects of cell therapy innovation, including discovery, genetic engineering, and early-to-mid stage product development. Notably, he has played instrumental roles in establishing and overseeing the development of innovative cell therapy platforms and products, encompassing NK cells, iPSC-derived T cells, and gamma delta T cells. His collaborative efforts with esteemed institutions like MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center have led to the advancement of novel CAR-T and CAR NK cell therapies for diverse cancer types. Additionally, he has spearheaded the development of cutting-edge enabling technologies such as viral vectors and CRISPR approaches, contributing to the evolution of cell therapy research and development. As a member of the Cell Therapy Translational Engine Leadership Team, he drives the translation of innovative cell therapies from discovery to clinical development, cementing their leadership in the field. 

 

 

Company introduction

• Teneura Therapeutics

Teneura Therapeutics is a pre-phase I company focused on developing treatments for patients with difficult-to-treat autoimmune conditions. Founded as an academic spin-off, Teneura Therapeutics develops autologous T cell therapies for difficult-to-treat neurological autoimmune disorders.

Its clinical pipeline includes NMDAR-CAAR (chimeric autoantibody receptor) for antigen-specific depletion of disease-causing B cells in NMDAR encephalitis and BCMA-CAR with improved antigen-sensitivity to cover a broad range of B cells for treatment of myasthenia gravis.

 

• Mabswitch

Mabswitch Inc. is a pioneering biotechnology company at the forefront of developing cutting-edge regulatable T-cell immunotherapies. With a primary focus on oncology, targeting both blood and solid cancers, Mabswitch also extends its efforts into addressing chronic diseases such as autoimmune and infectious diseases. Central to Mabswitch's innovation is its proprietary Universal Allosteric-linker and Switch Module for Antibodies (UNASMA) technology. This groundbreaking invention enables affinity tuning of antibody single-chain variable fragments (scFv) under physiological conditions via the exogenous administration of a peptide or small molecule ligand. This technology opens up new avenues for therapeutic interventions, providing unparalleled control and adaptability in treatment strategies. Mabswitch's flagship program, funded by the US National Cancer Institute (NCI), is focused on the development of a Switchable Affinity CAR-T cell therapy (SaefCAR) platform. Additionally, the company is developing a Switchable Affinity T-Cell Engager (SaefTE) platform. 

 

• Immunofoco

Immunofoco is a clinical-stage biotech company, devoted to bringing revolutionary immune cell drugs to patients with solid tumors. The operation started in September 2020, with the founding members combined the mavens from the industry, academia, business, and medical professions, and the executive committees had their hands on all the critical activities in advancing the regulatory approval of the first CAR-T drug in China.

 

• Celyad Oncology

Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor (CAR) T-cell therapies for cancer. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. 

Its proprietary short hairpin RNA (shRNA) platform, offering a differentiated strategy to future development of CAR T-cell therapies.  Manipulating protein expression to generate cells with a specific desired feature is one of the central goals of engineered cell therapy. Short hairpin RNA (shRNA) is a well-established approach to reduce protein expression by silencing genes in a process called RNA interference.

 

• Allife Medicine

Allife Medicine is an international pharmaceutical company founded by scientists from China and the United Kingdom specialising in induced pluripotent stem cell (iPSC) technology and aiming to develop affordable, innovative, and universally applicable cell and gene therapies. 

Allife Medicine has received multiple awards in Cell and Gene Therapies (CGT) in China and internationally and was recognised as the most influential company in the CGT sector in 2022-China, GHP2023 and LSR2024. 

 

• Hemostemix

Hemostemix's Angiogenic Cell Precursors ("ACP") are a breakthrough autologous (patient's own) treatment for heart disease and chronic limb threatening ischemia (“CLTI”).

In four heart studies, ACPs improved heart function up to 27% as measured by ejection fraction. In its Phase 2 CLTl trial, those patients presenting with ulcers prior to treatment demonstrated a significant decrease of ulcer size (p=0.01) by 3 months, and decreased amputation and death rate, compared to no significant decrease in the size of ulcers of the placebo group (p <0.54).

 

To register as Audiences:

Please click: https://us06web.zoom.us/webinar/register/2017072024107/WN_x-BN1WsyTy6kiWKW9qpTSA